CRISPR Therapeutics Files 8-K on Executive and Board Changes
Ticker: CRSP · Form: 8-K · Filed: May 23, 2024 · CIK: 1674416
Sentiment: neutral
Topics: corporate-governance, executive-changes, board-changes
Related Tickers: CRSP
TL;DR
CRISPR Therapeutics filed an 8-K on 5/23/24 detailing executive and board changes.
AI Summary
CRISPR Therapeutics AG filed an 8-K on May 23, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
FAQ
What specific items are being reported under the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' section?
The filing indicates that these items are being reported, but the specific details of departures, elections, appointments, and compensatory arrangements are not provided in this summary.
What is the primary business of CRISPR Therapeutics AG?
CRISPR Therapeutics AG is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
Where is CRISPR Therapeutics AG's principal executive office located?
The principal executive offices are located at Baarerstrasse 14, 6300 Zug, Switzerland.
What is the fiscal year end for CRISPR Therapeutics AG?
The fiscal year end for CRISPR Therapeutics AG is December 31 (1231).
What is the telephone number for CRISPR Therapeutics AG's principal executive offices?
The telephone number is 41 (0)41 561 32 77.
Filing Stats: 1,332 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-05-23 08:14:37
Key Financial Figures
- $460,000 — Bruno will receive an annual salary of $460,000 and she will be eligible to participate
Filing Documents
- crsp-20240523.htm (8-K) — 54KB
- crsp-ex10_1.htm (EX-10) — 140KB
- 0000950123-24-005877.txt ( ) — 331KB
- crsp-20240523.xsd (EX-101.SCH) — 26KB
- crsp-20240523_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1* Employment Agreement, dated May 23, 2024, by and between CRISPR Therapeutics, Inc. and Julianne Bruno 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CRISPR Therapeutics AG Date: May 23, 2024 By: /s/ Samarth Kulkarni Samarth Kulkarni, Ph.D. Chief Executive Officer